Synthesis of pharmacophores containing a prolinate core using a multicomponent 1,3-dipolar cycloaddition of azomethine ylides

Elisabet Selva [a, b, c], Luis M. Castelló [c], Juan Mancebo-Aracil [d], Verónica Selva [a, b], Carmen Nájera [a], Francisco Foubelo [a, b, **], José M. Sansano [a, b, *]

[a] Departamento de Química Orgánica and Centro de Innovación en Química Avanzada (ORFEO-CINQA), Facultad de Ciencias, Universidad de Alicante 03080 Alicante, Spain
[b] Instituto de Síntesis Orgánica, Facultad de Ciencias, Universidad de Alicante 03080 Alicante, Spain
[c] Medalchemy, S. L. Avenida Ancha de Castelar, 46 — EA, San Vicente del Raspeig, 03690, Alicante, Spain
[d] Departamento de Química, Universidad Nacional del Sur (UNS), Av. Alem 1253, CP: 8000, Bahía Blanca, Buenos Aires, Argentina

ARTICLE INFO

ABSTRACT

A multicomponent 1,3-dipolar cycloaddition between heterocyclic aldehydes, amino esters and dipolarophiles is efficiently promoted by silver acetate as catalyst, and depending on the nature of the heterocycle and its reactivity the reaction requires 70 °C or rt to complete. Selected pharmacophores anchored to a formyl group are chromone, 5-methoxyindole, pyridoxal surrogates and a very attractive uracyl derivative. The preference of each tested amino esters towards different dipolarophiles is discussed. At the end, a selective reduction of the ester group allows to obtain a very interesting dideoxiazanucleoside derivative.

© 2017 Elsevier Ltd. All rights reserved.

1. Introduction

The alarm of a drug antimicrobial resistance reported case reminds scientists the powerful evolution machinery in nature. Infections with resistant organisms are very difficult to treat, requiring costly and sometimes toxic alternatives. Bacteria, viruses, fungi, and parasites can cause disease among humans, other animals, and plants and have the ability to develop resistance to the drugs created against them. To face this problem when vaccines are not available, the development of new drugs as well as new diagnostic tests to track the origin and mechanism of resistance are prioritary.

Drug targets are usually proteins but are in some cases small regions of DNA or RNA. Synthetic nucleotides and nucleosides are currently being used to modify natural DNA/RNA sequences, altering specifically gene expression.[1] With this idea commercially available antiviral agents such as, for example, AZT, ribavirin, lamivudine, emtricitabine and stavudine incorporate mimetic heterocycles at the 2 position.[2,3] In addition, another different (non-commercial) compounds have shown interesting antiviral properties due to the presence of substituted pyridine/quinoline/quinazoline nucleus[4] or substituted indole/benzimidazole rings (see Fig. 1).[5] The synthesis of all these compounds require several steps and occasionally chemical yields are low.

In this work, the synthesis of prolinates and pseudo-azanucleosides bearing a mimetic nucleo-base anchored in the strategic position 5 and a nitrogen atom instead of the furan oxygen is designed.[6] The multicomponent[7,8] 1,3-dipolar cycloaddition (1,3-DC)[9] between heterocyclic aldehydes, amino esters and the corresponding dipolarophile was choiced as straightforward way[10] to access this new family of compounds **8**.[11] Apart from conventional hydrogen bonds between heterocycle and the genetic material of the microorganism, new additional biological interactions through the proline nitrogen atom can be envisaged.

Fig. 1. Synthetic nucleosides possessing high antiviral inhibition.

2. Results and discussion

This operationally simple multicomponent 1,3-DC started with the selection of four biologically attractive commercially available heterocyclic aldehydes 9–12 (Fig. 2) based on the important role in nature of chromones,[12] 5-methoxyindole,[13] pyridoxal[14] and uracyl[15] surrogates.

The optimization of the reaction was very simple[16] and only solvents (DCM, EtOH, PhMe, THF) and temperature (rt-110 °C range) were studied for all the formylheterocycles involved, silver acetate being necessary for the completion of the reaction. In general, to the solution (or suspension) of the free amino ester (or its hydrochloride), the aldehyde and triethylamine (1.1 equiv) in the corresponding solvent, the dipolarophile and silver acetate (5 mol %) were added in this order. Thus, 3-formyl-6-methylchromone (9) was tested in the presence of phenylalanine ethyl ester hydrochloride and N-methylmaleimide (NMM) as dipolarophile. Whilst the reaction did not occur neither at room temperature nor 70 °C in toluene, the expected endo-cycloadduct 8aa was obtained in 75% yield and 92:8 endo:exo ratio, after flash chromatography when the reaction was performed in refluxing ethanol (the best solvent for these series of compounds) for 10 h (Scheme 1). N-Benzylmaleimide (NBM) and methyl acrylate also gave good yields of cycloadducts 8ab (65%) and 8ac (76%), respectively (Scheme 1). Alanine methyl ester hydrochloride was allowed to react under this reaction conditions with maleimides giving rise to polycyclic compounds


Fig. 2. Commercially available formylheterocycles used in this work.

Scheme 1. Synthesis of compound 8a series bearing 4-chromenone nucleus.

endo-8ad and endo-8ae in 70 and 65% yields (Scheme 1). Unfortunately, the in situ generated imine from glycine methyl ester hydrochloride and aldehyde 9 afforded the expected cycloadduct in very low yield (<10% by analysis of ^{1}H NMR spectra of the crude mixture) unpurified with decomposed compounds and a noticeable amount (approx. 20% by ^{1}H NMR) of several stereoisomers of imidazolidine 13a as a result of the reaction of the imine with itself (Scheme 1). Compouds 8ab-8ae were isolated as unique endo-diastereoisomer (>95:5 dr).

5-Methoxyindole-3-carbaldehyde (10) behaved similarly to chromone 9. The cleanest reaction occurred in toluene at 70 °C in the presence of α-substituted amino esters with maleimides, triethylamine (1.1 equiv) and silver acetate (5 mol%) (Scheme 2). Thus, the combination with NMM and NBM with phenylalanine ethyl ester hydrochloride gave endo-cycloadducts 8ba and 8bb in moderate yield (52 and 55%, respectively). Alanine methyl ester hydrochloride also underwent 1,3-DC under standard conditions with NMM furnishing product endo-8bc in 60% yield (Scheme 2). Glycine methyl ester hydrochloride gave the corresponding mixture of stereoisomeric imidazolidines 13b (not drawn, approx. 20% by ^{1}H NMR) together with decomposed compounds and a small amount of the desired cycloadduct (<10% by analysis of ^{1}H NMR spectra of the crude mixture). Acrylates are not appropriate dipolarophiles in this particular transformation. As well as occurred in the last series, compouds 8ba-8ac were isolated as unique endo-diastereoisomer (>95:5 dr).

Pyridoxal hydrochloride (11·HCl) was the first example of a formylheterocycle able to react with glycine methyl ester hydrochloride under the standard reaction conditions in refluxing ethanol (best solvent). When this two reagents were combined

Scheme 2. Synthesis of compound **8b** series bearing 5-methoxyindole nucleus.

with triethylamine (2.2 equiv), NMM and silver acetate (5 mol%) in refluxing ethanol, cycloadduct endo-**8ca** was isolated in 96% yield (Scheme 3) and no traces of imidazolidine **13c** were detected. Phenylalanine ethyl ester hydrochloride reacted with maleimides producing endo-**8cb** and endo-**8 cc** in excellent yields and more than 95:5 endo:exo ratio (Scheme 3). Ethyl acrylate was required in order to prevent transesterification from the solvent. The reaction with **11**·HCl, the already mentioned acrylate and ethyl phenyl-alaninate furnished molecule **8cd** in very high yield (92%) and high diastereomeric ratio (90:10 endo:exo) (Scheme 3). It is noteworthy that the two hydroxyl groups of the pyridoxal **11** were not protected previously to the cycloaddition, which demonstrated a high functional group tolerance.

The 1,3-DCs involving 5-formyluracil (**12**) are perhaps the most

attractive series because it resembles the natural uridine nucleo-side. The multicomponent reaction was implemented at room temperature in a different way to the reactions run before. Toluene was the most appropriate solvent. Glycine methyl ester hydro-chloride reacted with maleimides and **12** to give endo-cycloadducts **8da** and endo-**8db** in 82 and 88% yield, respectively (Scheme 4, eq. (1)). When phenylalanine ethyl ester was employed as free amine, base was not needed and the reaction was completed in 10 h. NMM, NBM and methyl acrylate were appropriate dipolarophiles to access the interesting azanucleosidic agents **8dc**-**8de** (Scheme 4, eq. (2)). The high yields achieved in all these examples were obtained after recrystallization/precipitation from warm ethanol taking advan-tage of the poor solubility of molecules **8da**-**8de**. The preparation of compound endo-**8da** was also attempted in a 1.5 g scale obtaining the same chemical yield. All of the cycloadducts containing the uracyl moiety were isolated as unique endo-diastereoisomers (>95:5 dr).

The relative configuration of products **8** were determined by selective NOE experiments identifying clearly in the most repre-sentative examples of each series the all cis-arrangement typical of the major endo-approach of the dipolarophile to the intermediate W-shape conformer of the azomethine ylide. Moreover, all com-pounds described in this article are being tested as potential anti-bacterial, antitumor and antiviral agents.

To demonstrate the utility of this methodology the preparation of more similar structures to natural scaffolds such as endo-**14dc** was achieved by selective reduction of the ester group of the uracyl derivative endo-**8dc** in good yield (80%) using NaBH$_4$ in methanol

Scheme 3. Synthesis of compound **8c** series bearing a pyridoxal surrogate nucleus.

Scheme 4. Synthesis of compound **8d** series bearing a uracil nucleus.

Scheme 5. Synthesis of mimetic dideoxiazanucleoside *endo*-**14dc**.

under reflux of THF for 10 h (Scheme 5).[17,18]

3. Conclusions

According to all these results we can conclude that a large family of azanucleosides can be efficiently and easily prepared in a multicomponent process from readily accessible starting compounds. The versatility of the 1,3-DC has been demonstrated once more allowing the presence of many functional groups ensuring a 2,4,5-*cis*-arrangement or *all*. Among this, the operational simplicity of this procedure permits its implementation in a larger scale. A reduction of the ester group can be the key to new family of potential drugs whose study of activity is in their infancy. The asymmetric 1,3-DC version of these transformations is a difficult task and are currently underway.

4. Experimental section

4.1. General

All commercially available reagents and solvents were used without further purification, only aldehydes were also distilled prior to use. Analytical TLC was performed on Schleicher & Schuell F1400/LS 254 silica gel plates, and the spots were visualised under UV light ($\lambda = 254$ nm). Flash chromatography was carried out on handpacked columns of Merck silica gel 60 (0.040–0.063 mm). Melting points were determined with a Reichert Thermovar hot plate apparatus and are uncorrected. The structurally most important peaks of the IR spectra (recorded using a Nicolet 510 P-FT) are listed and wave numbers are given in cm^{-1}. NMR spectra were obtained using a Bruker AC-300 or AC-400 and were recorded at 300 or 400 MHz for ^{1}H NMR and 75 or 100 MHz for ^{13}C NMR, using CDCl$_3$ or DMSO-d_6 as solvent and TMS as internal standard (0.00 ppm). The following abbreviations are used to describe peak patterns where appropriate: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet or unresolved and br s = broad signal. All coupling constants (J) are given in Hz and chemical shifts in ppm. ^{13}C NMR spectra were referenced to CDCl$_3$ at 77.16 ppm. DEPT-135 experiments were performed to assign CH, CH$_2$ and CH$_3$. Low-resolution electron impact (EI) mass spectra were obtained at 70 eV using a Shimadzu QP-5000 by injection or DIP; fragment ions in m/z are given with relative intensities (%) in parentheses. High-resolution mass spectra (HRMS) were measured on an instrument using a quadrupole time-of-flight mass spectrometer (QTOF) and also through the electron impact mode (EI) at 70 eV using a Finnigan VG Platform or a Finnigan MAT 95 S. Microanalyses were performed in a Thermo Finnigan Flash 1112 Series.

4.2. General procedure for the synthesis of products **8a** and **8b**

To a stirred solution of amino ester hydrochloride (1.1 equiv, 0.6 mmol) in EtOH (3 mL, for **8a**) or toluene (3 mL, for **8b**), aldehyde (1 equiv, 0.5 mmol) was added. After that, Et$_3$N (1.1 equiv, 70 μL), the dipolarophile (1 equiv, 0.5 mmol) and AgOAc (5 mol%) were

added in this order. The reaction mixture was stirred overnight at 70 °C. The solvent was evaporated under reduced pressure. The crude mixture was extracted with ethyl acetate and washed with brine. The organic phase was dried (MgSO$_4$), filtrated and evaporated. The corresponding pyrrolidines were obtained in good yields after purification by flash chromatography (Hex/AcOEt).

4.2.1. (1S*,3R*,3aS*,6aR*)-Ethyl 1-benzyl-5-methyl-3-(6-methyl-4-oxo-4H-chromen-3-yl)-4,6-dioxooctahydropyrrolo[3,4-c]pyrrolo-1-carboxylate (**8aa**)

White solid, (178 mg, 75% yield). IR (neat) υ$_{max}$: 730, 1098, 1288, 1436, 1484, 1642, 1703, 1736, 2959 cm^{-1}.^{1}H NMR (300 MHz, CDCl$_3$) δ: 1.41 (t, J = 7.2 Hz, 3H), 2.45 (s, 3H), 2.84 (s, 3H), 3.19 (d, J = 13.7 Hz, 1H), 3.48 (d, J = 7.2 Hz 1H), 3.57 (d, J = 13.7 Hz, 1H), 3.75 (br s, 1H), 4.35 (q, J = 8.5 Hz, 2H), 4.90 (d, J = 9.0 Hz, 1H), 7.20−7.26 (m, 5H), 7.33 (d, J = 8.6 Hz, 1H), 7.48 (dd, J = 8.6, 2.3 Hz, 1H) 7.96 (s, 1H), 8.01 (d, J = 0.9 Hz, 1H). ^{13}C NMR (75 MHz, CDCl$_3$) δ: 14.1, 21.0, 25.1, 40.1, 47.5, 54.1, 62.0, 71.3, 77.3, 118.0, 123.0, 125.1, 127.6, 128.9, 129.6, 129.8, 134.9, 135.2, 135.4, 152.9, 154.7, 170.3, 174.6, 175.2, 177.6. LRMS (EI): m/z = 474 (M$^+$, >1%), 401 (14), 384 (23), 383 (100), 337 (34), 252 (14), 91 (22). HRMS (EI): calcd. for [C$_{27}$H$_{26}$N$_2$O$_6$] 474.1791; found 474.1781.

4.2.2. (1S*,3R*,3aS*,6aR*)-Ethyl 1,5-dibenzyl-3-(6-methyl-4-oxo-4H-chromen-3-yl)-4,6-dioxooctahydropyrrolo[3,4-c]pyrrolo-1-carboxylate (**8ab**)

Yellow solid, (179 mg, 65% yield). IR (neat) υ$_{max}$: 709, 1173, 1345, 1398, 1484, 1640, 1707, 1736, 2933 cm^{-1}.^{1}H NMR (300 MHz, CDCl$_3$) δ: 1.42 (t, J = 7.2 Hz, 3H), 2.48 (s, 3H), 3.15 (d, J = 13.7 Hz, 1H), 3.47 (d, J = 7.7 Hz, 1H), 3.59 (d, J = 13.7 Hz, 1H), 3.87 (d, J = 7.6 Hz, 1H), 4.36 (q, J = 7.1 Hz, 2H), 4.54 (q, J = 14.1 Hz, 2H), 4.98 (d, J = 8.8 Hz, 1H), 7.16−7.32 (m, 11H), 7.49 (dd, J = 8.6, 2.1 Hz, 1H) 7.62 (s, 1H), 8.06 (d, J = 2.2 Hz, 1H). ^{13}C NMR (75 MHz, CDCl$_3$) δ: 14.2, 21.0, 40.1, 42.5, 46.9, 53.9, 61.8, 71.1, 77.3, 117.9, 123.0, 125.2, 127.5, 127.9, 128.5, 128.6, 128.7, 128.9, 129.6, 135.0, 135.1, 135.2, 135.7, 152.7, 154.6, 170.5, 174.2, 174.9, 177.4. LRMS (EI): m/z = 550 (M$^+$, >1%), 447 (16), 460 (31), 459 (100), 413 (46), 252 (26), 91 (92). HRMS (EI): calcd. for [C$_{33}$H$_{30}$N$_2$O$_6$] 550.2104; found 550.2078.

4.2.3. (2R*,4S*,5R*)-2-Ethyl 4-methyl 2-benzyl-5-(6-methyl-4-oxo-4H-chromen-3-yl)pyrrolidine-2,4-dicarboxylate (**8ac**)

Yellow oil, (170 mg, 76% yield). IR (neat) υ$_{max}$: 1198, 1437, 1485, 1619, 1645, 1733, 2251, 2950, 2981, 3339 cm^{-1}.^{1}H NMR (300 MHz, CDCl$_3$) δ: 1.25 (t, J = 7.1 Hz, 3H), 2.26 (dd, J = 13.6, 7.7 Hz, 1H), 2.42 (s, 3H), 2.75 (dd, J = 13.6, 4.7 Hz, 1H), 3.01 (d, J = 13.4 Hz, 1H), 3.18 (d, J = 13.4 Hz, 1H), 3.31 (s, 3H), 3.54 (td, J = 7.5, 4.8 Hz, 1H), 4.18 (tq, J = 7.2, 3.4 Hz, 3H), 4.79 (d, J = 7.5 Hz, 1H), 7.14−7.33 (m, 5H), 7.32 (d, J = 8.6 Hz, 1H), 7.45 (dd, J = 8.6, 2.0 Hz, 1H), 7.97 (d, J = 1.3 Hz, 1H), 8.08 (s, 1H). ^{13}C NMR (75 MHz, CDCl$_3$) δ: 14.2.21.0, 38.9, 45.0, 47.1, 51.5, 56.5, 61.3, 69.3, 117.9, 123.1, 125.1, 127.0, 128.2, 128.3, 130.0, 135.0, 135.1, 136.5, 153.5, 154.6, 173.1, 174.8, 177.2. LRMS (EI): m/z = 449 (M$^+$, >1%), 376 (27), 359 (21), 358 (100), 280 (15), 259 (52), 252 (26), 226 (15), 91 (33). HRMS (EI): calcd. for [C$_{26}$H$_{27}$NO$_6$] 449.1838; found 449.1840.

4.2.4. (1S*,3R*,3aS*,6aR*)-Methyl 1,5-dimethyl-3-(6-methyl-4-oxo-4H-chromen-3-yl)-4,6-dioxooctahydropyrrolo[3,4-c]pyrrolo-1-carboxylate (**8ad**)

Pale brown solid, (134 mg, 70% yield). IR (neat) υ$_{max}$: 709, 1173, 1345, 1398, 1484, 1640, 1707, 1736, 2933.^{1}H NMR (300 MHz, CDCl$_3$) δ: 1.70 (s, 3H), 2.44 (s, 3H), 2.86 (s, 3H), 3.35 (d, J = 7.7 Hz, 1H), 3.78 (t, J = 8.2 Hz, 1H), 3.88 (s, 3H), 4.88 (d, J = 8.9 Hz, 1H), 7.35 (d, J = 8.6 Hz, 1H), 7.49 (dd, J = 8.6, 2.2 Hz, 1H), 7.95 (dd, J = 2.0, 1.0 Hz, 1H), 8.08 (s, 1H). ^{13}C NMR (75 MHz, CDCl$_3$) δ: 21.1, 23.0, 25.4, 48.2, 53.4, 55.8, 57.6, 68.5, 118.1, 123.1, 125.1, 135.7, 135.9, 154.2, 154.8,

171.2, 174.5, 175.0, 178.5. LRMS (EI): $m/z = 384$ (M$^+$, >1%), 369 (18), 326 (20), 325 (100), 273 (19), 266 (26), 213 (23), 119 (21). HRMS (EI): calcd. for [C$_{20}$H$_{20}$N$_2$O$_6$] 384.1321; found 384.1305.

4.2.5. (1S*,3R*,3aS*,6aR*)-Methyl 5-benzyl-1-methyl-3-(6-methyl-4-oxo-4H-chromen-3-yl)-4,6-dioxooctahydropyrrolo[3,4-c]pyrrole-1-carboxylate (8ae)

Yellow solid, (150 mg, 65% yield). IR (neat) υ$_{max}$: 700, 1170, 1344, 1399, 1485, 1640, 1705, 1740, 2952.^{1}H NMR (300 MHz, CDCl$_3$) δ: 1.72 (s, 3H), 2.46 (s, 3H), 3.35 (d, $J = 7.9$ Hz, 1H), 3.79 (d, $J = 8.6$ Hz, 1H), 3.85 (s, 3H), 4.50 (d, $J = 4.8$ Hz, 1H), 5.01 (d, $J = 6.3$ Hz, 1H), 7.26–7.30 (m, 6H), 7.34 (d, $J = 8.6$ Hz, 1H), 7.50 (dd, $J = 8.6, 2.0$ Hz, 1H), 7.95 (s, 1H). ^{13}C NMR (75 MHz, CDCl$_3$) δ: 21.0, 22.8, 42.9, 47.6, 53.3, 55.2, 56.7, 68.2, 118.0, 122.9, 125.1, 128.0, 128.5, 128.7, 128.9, 135.4, 135.6, 135.7, 154.2, 154.7, 171.0, 174.0, 174.6, 178.2. LRMS (EI): $m/z = 460$ (M$^+$, >1%), 445 (24), 402 (27), 401 (100), 273 (33), 266 (70), 240 (28), 213 (26), 91 (74). HRMS (EI): calcd. for [C$_{26}$H$_{24}$N$_2$O$_6$] 460.1634; found 460.1629.

4.2.6. (1S*,3R*,3aS*,6aR*)-Ethyl 1-benzyl-3-(5-methoxy-1H-indol-3-yl)-5-methyl-4,6-dioxooctahydropyrrolo[3,4-c]pyrrole-1-carboxylate (8ba)

Grey solid, (119 mg, 52% yield). IR (neat) υ$_{max}$: 703, 1214, 1381, 1283, 1437, 1485, 1704, 2938, 3375.^{1}H NMR (300 MHz, CDCl$_3$) δ: 1.26 (t, $J = 7.2$ Hz, 3H), 2.98 (s, 3H), 3.30 (d, $J = 13.4$ Hz, 1H), 3.37–3.44 (m, 1H), 3.48–3.54 (m, 1H), 3.51 (d, $J = 13.7$ Hz, 1H), 3.82 (s, 3H), 4.16 (q, $J = 7.2$ Hz, 2H), 4.86 (d, $J = 6.4$ Hz, 1H), 6.85 (dd, $J = 8.9$, 2.4 Hz, 1H), 7.16 (s, 1H), 7.22–7.36 (m, 7H), 8.18 (s, 1H). ^{13}C NMR (75 MHz, CDCl$_3$) δ: 14.1, 25.2, 40.0, 48.9, 54.0, 55.7, 56.5, 62.5, 71.5, 100.3, 112.3, 112.7, 126.0, 127.8, 128.3, 128.9, 130.1, 131.1, 131.5, 134.7, 153.9, 174.2, 174.5, 175.1. LRMS (EI): $m/z = 461$ (M$^+$, >1%), 388 (67), 371 (23), 370 (100), 350 (28), 212 (20), 185 (30), 147 (22), 91 (27). HRMS (EI): calcd. for [C$_{26}$H$_{27}$N$_3$O$_5$] 461.1951; found 461.1941.

4.2.7. (1S*,3R*,3aS*,6aR*)-Ethyl 1,5-dibenzyl-3-(5-methoxy-1H-indol-3-yl)-4,6- dioxooctahydropyrrolo[3,4-c]pyrrole-1-carboxylate (8bb)

Brown solid, (148 mg, 55% yield). IR (neat) υ$_{max}$: 701, 1174, 1211, 1396, 1704, 2932, 3348.^{1}H NMR (300 MHz, CDCl$_3$) δ: 1.43 (t, $J = 7.2$ Hz, 3H), 3.18 (d, $J = 13.5$ Hz, 1H), 3.48–3.60 (m, 3H), 3.87 (s, 3H), 4.32 (d, $J = 14.1$ Hz, 1H), 4.39 (qd, $J = 7.2, 1.0$ Hz, 2H), 4.47 (d, $J = 14.1$ Hz, 1H), 5.17 (d, $J = 8.9$ Hz, 1H), 6.76 (d, $J = 2.5$ Hz, 1H), 6.84 (dd, $J = 8.9, 2.5$ Hz, 1H), 7.22–7.30 (m, 12H), 8.36 (s, 1H). ^{13}C NMR (75 MHz, CDCl$_3$) δ: 14.2, 40.1, 42.6, 49.0, 54.9, 52.2, 55.9, 61.7, 71.1, 100.9, 111.8, 112.2, 112.4, 127.4, 127.8, 128.5, 128.8, 128.9, 129.8, 135.4, 135.7, 153.9, 171.2, 174.7, 175.6. LRMS (EI): $m/z = 537$ (M$^+$, >1%), 464 (13), 447 (16), 446 (57), 444 (20), 351 (23), 350 (100), 276 (29), 212 (22), 185 (37), 158 (21), 91 (65). HRMS (EI): calcd. for [C$_{32}$H$_{31}$N$_3$O$_5$] 537.2264; found 537.2244.

4.2.8. (1S*,3R*,3aS*,6aR*)-Methyl-3-(5-methoxy-1H-indol-3-yl)-1,5-dimethyl-4,6-dioxooctahydropyrrolo[3,4-c]pyrrole-1-carboxylate (8bc)

Brown solid, (110 mg, 60% yield). IR (neat) υ$_{max}$: 1289, 1439, 1702, 1751, 2957, 3265.^{1}H NMR (300 MHz, CDCl$_3$) δ: 1.62 (s, 3H), 2.72 (s, 3H), 3.33 (d, $J = 7.6$ Hz, 1H), 3.57 (dd, $J = 9.1, 7.5$ Hz, 1H), 3.82 (s, 3H), 3.89 (s, 3H), 5.04 (d, $J = 9.1$ Hz, 1H), 6.80 (dd, $J = 8.8, 2.4$ Hz, 1H), 7.00 (d, $J = 2.4$ Hz, 1H), 7.05 (d, $J = 2.1$ Hz, 1H), 7.15 (d, $J = 8.8$ Hz, 1H), 8.45 (s, 1H). ^{13}C NMR (75 MHz, CDCl$_3$) δ: 23.9, 25.1, 50.4, 52.8, 55.8, 56.5, 56.9, 67.4, 100.8, 111.6, 112.4, 112.5, 123.4, 126.5, 131.8, 154.0, 173.2, 175.3, 176.3. LRMS (EI): $m/z = 371$ (M$^+$, >1%), 269 (20), 261 (16), 260 (100), 200 (62), 185 (63), 169 (29), 159 (40). HRMS (EI): calcd. for [C$_{19}$H$_{21}$N$_3$O$_5$] 371.1481; found 371.1473.

4.3. General procedure for the synthesis of product 8c

To a stirred solution of ester hydrochloride as amine (1.1 equiv, 0.5 mmol) in EtOH (3 mL) was added pyridoxal hydroclorhide (1 equiv, 0.5 mmol). After, Et$_3$N (2 equiv, 140 μL), dipolarophile (1 equiv, 0.5 mmol) and AgOAc (5 mol%). The reaction mixture was stirred overnight at 70 °C. The solvent was removed under reduced pressure. The crude mixture was extracted with ethyl acetate and was washed with brine. The organic phase was dried (MgSO$_4$) and after filtration and evaporation, the corresponding pyrrolidines were obtained without purification.

4.3.1. (1R*,3S*,3aR*,6aS*)-Methyl 5-benzyl-3-(3-hydroxy-5-(hydroxymethyl)-2-methylpyridin-4-yl)-4,6-dioxooctahydropyrrolo[3,4-c]pyrrole-1-carboxylate (8ca)

Yellow solid, (110 mg, 96% yield). IR (neat) υ$_{max}$: 1211, 1393, 1714, 1745, 2802, 3264.^{1}H NMR (300 MHz, CDCl$_3$) δ: 2.26 (s, 3H), 3.50–3.73 (m, 2H), 3.77 (s, 3H), 4.09 (d, $J = 7.5$ Hz, 1H), 4.40 (d, $J = 14.3$ Hz, 1H), 4.51 (d, $J = 14.3$ Hz, 1H), 4.90 (d, $J = 8.9$ Hz, 1H), 7.22–7.28 (m, 5H), 7.71 (s, 1H). ^{13}C NMR (75 MHz, CDCl$_3$) δ: 18.3, 43.1, 47.1, 48.4, 52.6, 59.3, 61.0, 61.3, 126.1, 128.0, 128.5, 129.0, 132.0, 134.9, 138.6, 148.6, 152.7, 169.6, 174.8, 175.0. LRMS (EI): $m/z = 425$ (M$^+$, >1%), 348 (30), 337 (30), 220 (44), 215 (22), 187 (40), 165 (18), 161 (100), 150 (31), 139 (17), 91 (95). HRMS (EI): calcd. for C$_{22}$H$_{23}$N$_3$O$_6$ [M − CH$_3$O, - CO$_2$CH$_3$] 336.1336; found 336.1348.

4.3.2. (1R*,3S*,3aR*,6aS*)-Ethyl 1-benzyl-3-(3-hydroxy-5-(hydroxymethyl)-2-methylpyridin-4-yl)-5-methyl-4,6-dioxooctahydropyrrolo[3,4-c]pyrrole-1-carboxylate (8cb)

Pale green solid, (204 mg, 90% yield). IR (neat) υ$_{max}$: 731, 1096, 1198, 1288, 1385, 1437, 1702, 1739, 2664, 2942, 3302.^{1}H NMR (300 MHz, CDCl$_3$) δ: 1.38 (t, $J = 7.1$ Hz, 3H), 2.78 (s, 3H), 2.32 (s, 3H), 3.10 (d, $J = 13.8$ Hz, 1H), 3.50 (d, $J = 7.9$ Hz, 1H), 3.69 (d, $J = 13.9$ Hz, 1H), 3.98 (t, $J = 8.6$ Hz, 1H), 4.34 (q, $J = 7.0$ Hz, 2H), 4.63 (q, $J = 13.2$ Hz, 2H), 5.34 (d, $J = 9.8$ Hz, 1H), 7.17–7.28 (m, 5H), 7.74 (s, 1H). ^{13}C NMR (75 MHz, CDCl$_3$) δ: 14.1, 17.9, 25.1, 40.5, 48.5, 53.7, 57.0, 61.0, 62.4, 71.1, 127.9, 128.1, 129.4, 129.6, 133.0, 134.2, 137.3, 147.9, 153.2, 170.1, 174.3, 174.4. LRMS (EI): $m/z = 453$ (M$^+$, >1%), 362 (22), 345 (19), 344 (100), 187 (24), 91 (17). HRMS (EI): calcd. for [C$_{24}$H$_{27}$N$_3$O$_6$] 453.1900; found 453.1922.

4.3.3. (1S*,3R*,3aR*,6aS*)-Ethyl 1,5-dibenzyl-3-(3-hydroxy-5-(hydroxymethyl)-2-methylpyridin-4-yl)-4,6-dioxooctahydropyrrolo[3,4-c]pyrrole-1-carboxylate (8 cc)

Pale green solid, (225 mg, 85% yield). IR (neat) υ$_{max}$: 702, 1200, 1349, 1397, 1708, 1736, 2658, 2935, 3298.^{1}H NMR (300 MHz, CDCl$_3$) δ: 1.35 (t, $J = 7.1$ Hz, 3H), 2.31 (s, 3H), 2.99 (d, $J = 14.0$ Hz, 1H), 3.48 (d, $J = 7.8$ Hz, 1H), 3.72 (d, $J = 13.8$ Hz, 1H), 3.95 (t, $J = 8.3$ Hz, 1H), 4.34–4.36 (m, 1H), 4.53 (d, $J = 14.0$ Hz, 1H), 5.27 (d, $J = 9.7$ Hz, 1H), 7.14–7.34 (m, 10H), 7.81 (s, 1H). ^{13}C NMR (75 MHz, CDCl$_3$) δ: 14.0, 40.9, 43.1, 48.1, 53.8, 57.1, 59.4, 62.7, 71.5, 128.1, 128.6, 128.7, 129.1, 129.2, 129.4, 130.0, 134.3, 134.6, 135.7, 137.8, 142.2, 155.9, 170.1, 173.5, 173.9. LRMS (EI): $m/z = 529$ (M$^+$, >1%), 438 (14), 421 (26), 420 (100), 187 (26), 91 (65). HRMS (EI): calcd. for C$_{30}$H$_{31}$N$_3$O$_6$ [M − CH$_3$O] 498.2029; found 498.2026.

4.3.4. (2R*,4S*,5R*)-Diethyl 2-benzyl-5-(3-hydroxy-5-(hydroxymethyl)-2-methylpyridin-4-yl)pyrrolidine-2,4-dicarboxylate (8cd)

Yellow oil, (203 mg, 92% yield). IR (neat) υ$_{max}$: 702, 1029, 1189, 1378, 1735, 2664, 2981, 3322.^{1}H NMR (300 MHz, CDCl$_3$) δ: 0.81 (t, $J = 7.2$ Hz, 3H), 1.27 (t, $J = 7.2$ Hz, 3H), 2.27–2.42 (m, 4H), 2.90–2.99 (m, 2H), 3.39 (d, $J = 13.7$ Hz, 1H), 3.52 (td, $J = 8.3, 4.6$ Hz, 1H), 3.70 (qd, $J = 7.2, 2.5$ Hz, 2H), 4.23 (q, $J = 7.1$ Hz, 2H), 4.50 (d, $J = 13.0$ Hz, 1H), 4.62 (d, $J = 13.0$ Hz, 1H), 5.19 (d, $J = 8.6$ Hz, 1H), 6.87–7.39 (m,

5H), 7.68 (s, 1H). ^{13}C NMR (75 MHz, CDCl$_3$) δ: 13.6, 14.1, 16.2, 38.5, 44.4, 47.6, 59.7, 59.9, 61.4, 61.9, 69.6, 127.8, 129.1, 129.1, 129.7, 132.1, 132.4, 135.0, 135.3, 154.9, 171.3, 173.9. LRMS (EI): m/z = 442 (M$^+$, >1%), 351 (23), 333 (53), 323 (31), 305 (100), 287 (62), 259 (17), 91 (41). HRMS (EI): calcd. for C$_{24}$H$_{30}$N$_2$O$_6$ [M − CH$_3$O, - OH] 394.1534; found 394.1529.

4.4. General procedure for the synthesis of products **8d**

8da-8db: to a stirred solution of ester hydrochloride as amine (1.1 equiv, 0.6 mmol) in toluene (2 mL) was added 5-formyluracile (1 equiv, 0.5 mmol) and Et$_3$N (1.1 equiv). After that, dipolarophile (1.0 equiv) and AgOAc (5 mol%). The reaction mixture was stirred overnight at room temperature. The solvent was removed under reduced pressure. The crude mixture was filtrated through Celite with warm EtOH to furnish the corresponding product. To remove the ammonium salt, it was washed with DCM.

8dc-8de: to a stirred solution of free amine ester (1 equiv was previously isolated: 1 equiv of the corresponding hydrochloride with 1.3 equiv K$_2$CO$_3$, in a mixture of AcOEt/H$_2$O during 1 h. It was washed with water and the organic fase evaporated), in toluene (2 mL) was added 5-formyluracile (1 equiv, 0.5 mmol). After that, dipolarophile (1.0 equiv, 0.5 mmol) and AgOAc (5 mol%). The solvent was removed under reduced pressure. The crude mixture was filtrated through Celite with warm EtOH to furnish the corresponding product.

4.4.1. (1S*,3R*,3aS*,6aR*)-Methyl 3-(2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-5-methyl-4,6-dioxooctahydropyrrolo[3,4-c]pyrrole-1-carboxylate (8da)

Pale yellow solid, (132 mg, 82% yield). IR (neat) υ$_{max}$: 1098, 1223, 1439, 1694, 1741, 2978.^{1}H NMR (300 MHz, DMSO-d_6) δ: 2.66 (s, 3H), 3.39−3.44 (m, 1H), 3.53−3.56 (m, 1H), 3.67 (s, 3H), 3.92 (d, J = 7.1 Hz, 1H), 4.32 (d, J = 8.7 Hz, 1H), 7.19−7.27 (m, 4H). ^{13}C NMR (75 MHz, DMSO-d_6) δ: 24.6, 48.0, 49.1, 51.7, 61.0, 63.0, 127.4, 127.5, 128.0, 138.7, 171.8, 175.5, 176.9. LRMS (EI): m/z = 322 (M$^+$, >1%), 307 (30), 289 (46), 263 (69), 259 (17), 211 (93), 206 (51), 204 (41), 178 (24), 151 (93), 121 (46), 107 (28), 44 (100). LRMS (EI): calcd. for [C$_{13}$H$_{14}$N$_4$O$_6$] 322.0913; found 322.0924.

4.4.2. (1S*,3R*,3aS*,6aR*)-Methyl 5-benzyl-3-(2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-4,6-dioxooctahydropyrrolo[3,4-c]pyrrole-1-carboxylate (8db)

Pale yellow solid, (175 mg, 88% yield). IR (neat) υ$_{max}$: 1157, 1211, 1400, 1445, 1659, 1693, 1740, 3029.^{1}H NMR (300 MHz, DMSO-d_6) δ: 3.42 (d, J = 3.4 Hz, 1H), 3.46 (d, J = 8.3 Hz, 1H), 3.64 (d, J = 3.4 Hz, 1H), 3.67 (s, 3H), 3.97 (dd, J = 7.1, 4.2 Hz, 1H), 4.35 (dd, J = 7.1, 4.2 Hz, 1H), 4.41 (d, J = 4.0 Hz, 2H), 7.16−7.36 (m, 8H). ^{13}C NMR (75 MHz, DMSO-d_6) δ: 41.3, 47.6, 48.6, 51.4, 60.9, 62.7, 127.1, 127.3, 127.6, 128.2, 135.7, 138.2, 170.4, 174.9, 176.4. LRMS (EI): m/z = 398 (M$^+$, >1%), 383 (3), 365 (38), 339 (33), 211 (100), 206 (23), 204 (32), 187 (15), 151 (70), 106 (17), 91 (75). HRMS (EI): calcd. for C$_{19}$H$_{18}$N$_4$O$_6$ [M − H$^+$] 397.1158; found 397.1148.

4.4.3. (1S*,3R*,3aS*,6aR*)-Ethyl 1-benzyl-3-(2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-5-methyl-4,6-dioxooctahydropyrrolo[3,4-c]pyrrole-1-carboxylate (8dc)

Grey solid, (198 mg, 93% yield). IR (neat) υ$_{max}$: 1098, 1436, 1678, 1697, 3031.^{1}H NMR (300 MHz, DMSO-d_6) δ: 1.24 (t, J = 7.1 Hz, 3H), 2.65 (s, 3H), 2.89 (d, J = 6.7 Hz, 1H), 3.00 (d, J = 13.9 Hz, 1H), 3.16 (d, J = 14.0 Hz, 1H), 3.45−3.54 (m, 2H), 4.01−4.14 (m, 2H), 4.51 (d, J = 8.5 Hz, 1H), 7.11−7.23 (m, 8H), 7.39 (s, 1H). ^{13}C NMR (75 MHz, DMSO-d_6) δ: 15.2, 25.9, 50.5, 57.1, 57.6, 62.0, 62.2, 72.9, 126.6, 127.9, 128.1, 129.3, 129.6, 129.8, 130.2, 130.5, 131.4, 137.6, 165.8, 171.8, 177.1, 177.3. LRMS (EI): m/z = 426 (M$^+$, <1%), 353 (11), 336 (16), 335 (100),

289 (14), 206 (8), 91 (16). Elemental Analysis required for C$_{21}$H$_{22}$N$_4$O$_6$: C 59.20, H 5.20, N 13.10%; found: C 59.40, H 5.00, N 12.85%.

4.4.4. (1S*,3R*,3aS*,6aR*)-Ethyl 1,5-dibenzyl-3-(2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-4,6-dioxooctahydropyrrolo[3,4-c]pyrrole-1-carboxylate (8dd)

Yellow solid, (240 mg, 96% yield). IR (neat) υ$_{max}$: 1199, 1400, 1674, 1703, 3031.^{1}H NMR (300 MHz, DMSO-d_6) δ: 1.24 (t, J = 7.1 Hz, 3H), 3.09 (d, J = 13.9 Hz, 1H), 3.24 (d, J = 14.0 Hz, 1H), 3.57−3.68 (m, 2H), 4.04−4.12 (m, 2H), 4.37 (d, J = 14.0 Hz, 1H), 4.47 (d, J = 14.0 Hz, 1H), 4.61 (d, J = 8.5 Hz, 1H), 7.16−7.31 (m, 14H). ^{13}C NMR (75 MHz, DMSO-d_6) δ: 14.3, 42.1, 48.9, 55.6, 55.8, 61.2, 71.7, 127.1, 127.6, 127.7, 128.6, 128.8, 129.7, 130.5, 136.6, 136.2, 139.1, 151.5, 164.7, 170.8, 175.7, 176.1. LRMS (EI): m/z = 502 (M$^+$, <1%), 429 (9), 412 (23), 411 (100), 365 (9), 91 (63). Elemental Analysis required for C$_{27}$H$_{26}$N$_4$O$_6$: C 64.50, H 5.20, N 11.15%; found C 64.65, H 5.10, N 11.50%.

4.4.5. (2R*,4S*,5R*)- Ethyl 4-methyl 2-benzyl-5-(2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)pyrrolidine-2,4-dicarboxylate (8de)

Pale yellow solid, (180 mg, 90% yield). IR (neat) υ$_{max}$: 1202, 1438, 1676, 1719, 2977, 3061.^{1}H NMR (300 MHz, DMSO-d_6) δ: 1.18 (t, J = 7.1 Hz, 3H), 2.09 (dd, J = 13.9 Hz, 1H), 2.46 (dd, J = 14.0 Hz, 1H), 2.86−3.02 (m, 2H), 3.14−3.21 (m, 1H), 3.38 (s, 3H), 4.04−4.11 (m, 2H), 4.39 (d, J = 8.5 Hz, 1H), 7.20−7.28 (m, 8H), 7.39 (s, 1H). ^{13}C NMR (75 MHz, DMSO-d_6) δ: 8.9, 14.5, 45.9, 47.3, 51.6, 56.8, 60.9, 69.1, 111.9, 127.0, 128.4, 130.3, 137.4, 138.2, 151.3, 164.1, 173.1, 174.7. LRMS (EI): m/z = 401 (M$^+$, <1%), 328 (19), 311 (15), 310 (100), 232 (23), 211 (7), 204 (8), 91 (27). HRMS (EI): calcd. for C$_{20}$H$_{23}$N$_3$O$_6$ [M − CO$_2$CH$_3$], 342.1460; found 342.1454.

4.5. General procedure for the synthesis of product **14dc**

Finely powdered sodium borohydride (6 equiv, 1.3 mmol) was suspended in THF (4 mL) in presence of the respective ester (100 mg, 0.2 mmol) during a period of 15 min under reflux (70 °C) and stirring. Then methanol (0.45 mL) was added dropwise during a period of 5 min and effervescence was observed. Stirring and reflux were maintained during a period of 10 h. After the end of the reaction, the alcohol was cooled to room temperature and quenched with a saturated solution of NH$_4$Cl. For purification the organic layer was separated and the aqueous phase extracted with DCM. The organic phase was dried (MgSO$_4$) and concentrated under low pressure to give the corresponding triol **14dc**.

4.5.1. 5-[(2R*,3R*,4R*,5S*)-5-Benzyl-3,4,5-tris(hydroxymethyl)-pyrrolidin-2-yl]pyrimidine-2,4(1H,3H)-dione (14dc)

Pale yellow solid, (65 mg, 80% yield). IR (neat) υ$_{max}$: 702, 1098, 1454, 1698, 1775, 2926, 3390.^{1}H NMR (300 MHz, DMSO-d_6) δ: 2.42 (dd, J = 13.2, 7.5 Hz, 1H), 2.55−2.59 (m, 1H), 2.64−2.67 (m, 3H), 2.81−2.84 (m, 1H), 3.03 (d, J = 10.5 Hz, 1H), 3.15−3.18 (m, 1H), 3.25 (td, J = 11.3, 10.5, 5.1 Hz, 4H), 3.45 (dd, J = 11.3, 3.3 Hz, 1H), 4.62 (d, J = 6.1 Hz, 1H), 4.88−5.07 (m, 3H), 7.20−7.32 (m, 8H). ^{13}C NMR (75 MHz, DMSO-d_6) δ: 34.8, 40.4, 54.6, 59.6, 60.5, 63.0, 66.0, 126.3, 126.7, 128.6, 128.9, 129.5, 129.6, 138.7, 140.1. LRMS (EI): m/z = 361 (M$^+$, <1%), 164 (29), 120 (21), 117 (37), 105 (13), 91 (100), 70 (25). HRMS (EI): calcd. for C$_{18}$H$_{23}$N$_3$O$_5$ [M − 2xCH$_2$O−− H$_2$O]: 282.1249; found 282.1260.

Acknowledgements

References

1. Nielsen MB, ed. *Organic Synthesis and Molecular Engineering*. Hoboken, New Jersey: John Wiley & Sons; 2014.
2. For updated list of HCV inhibitors in the market, see: https://www.drugs.com/drug-class/antiviral-agents.html
3. De Clercq E. *Nature Rev*. 2008;4:1001—1018.
4. (a) Calter MA, Zhu C. *J Org Chem*. 1999;64:1415—1419;
   (b) Chen JJ, Drach JC, Townsend LB. *J Org Chem*. 2003;68:4170—4178;
   (c) Li JS, Gold B. *J Org Chem*. 2005;70:8764—8771.
5. Chen JJ, Wei Y, Williams JD, Drach JC, Townsend LB. Nucleosides, nucleotides, and nucleic acids. 2005;24:1417—1437.
6. The introduction of these heterocyclic moieties (anchored to the dipolarophile) has been published after our patent application Yang Q-L, Xie M-S, Xia C, et al. *Chem Commun*. 2014;50:14809—14812.
7. For recent reviews dealing with multicomponent reactions, see: (a) van der Heijden G, Ruijter E, Orru RVA. *Synlett*. 2013;24:666—685;
   (b) Brauch S, van Berkel SS, Westermann B. *Chem Soc Rev*. 2013;42:4948—4962;
   (c) . In: Zhu J, Wang Q, Wang M-X, eds. *Multicomponent Reactions in Organic Synthesis*. Weinheim: Wiley-VCH; 2014;
   (d) . In: Müller TJJ, ed. *Science of Synthesis: Multicomponent Reactions*. Stuttgart: Thieme; 2014;
   (e) . In: Pérez-Herrera R, Marqués-López E, eds. *Multicomponent Reactions: Concepts and Applications for Design and Synthesis*. Weinheim: Wiley-VCH; 2015.
8. (a) Mancebo-Aracil J, Cayuelas A, Nájera C, Sansano JM. *Tetrahedron*. 2015;71:8804—8816;
   (b) Mancebo-Aracil J, Castelló LM, Nájera C, et al. *Tetrahedron*. 2015;71:9645—9661.
9. For recent 1,3-DC general reviews, see: (a) Ryan JH. *Arkivoc*. 2015;i:160—183;
   (b) Hashimoto T, Maruoka K. *Chem Rev*. 2015;115:5366—5412;
   (c) Pavlovska TL, Redkin RGr, Lipson VV, Atamanuk DV. *Synth Biol Activ Mol Divers*. 2016;20:299—344;
   (d) Meyer AG, Ryan JH. *Molecules*. 2016;21:935—989;
   (e) Singh MS, Chowdhury S, Koley S. *Tetrahedron*. 2016;72:1603—1716;
   (f) Nájera C, Sansano JM. *Chem Rec*. 2016;16:2430—2448;
   (g) Dondas HA, Retamosa MG, Sansano JM. *Synthesis*. 2017;49:2819—2851;
   (h) Bdiri B, Zhao B-J, Zhou Z-M. *Tetrahedron Asymmetry*. 2017;28:876—883.
10. (a) Nájera C, Sansano JM. *Org Biomol Chem*. 2009;7:4567—4581;
    (b) Nájera C, Sansano JM. *L'Actualité Chim*. 2013;370:28—30.
11. Preliminary results were previously patented. Mancebo-Aracil J, Castelló LM, Nájera C, Sansano JM. WO2014154921 (A1), March, 2014.
12. 4-Chromenone nucleus is present in flavones, which can be considered antioxidant agents, have also effects on CYP (P450) activity, coronary heart disease prevention, hepatoprotective, anti-inflammatory, and anticancer activities, antiviral activitiy, etc. In plant systems, flavonoids help in combating oxidative stress and act as growth regulators Kumar S, Pandey AK. *Sci World J*. 2013;2013:1—8.
13. Serotonin is as a neurotransmitter that modulates neural activity and a wide range of neuropsychological processes Berger M, Gray JA, Roth BL. *Annu Rev Med*. 2009;60:355—366.
14. Percudani R, Peracchi A. EMBO reports. *Pyridoxal Phosphate Represents the Most Versatile Organic Cofactor in Biology, and Is Used by a Variety of Enzymes in All Organisms*. vol. 4. 2003:850—854.
15. Antiviral and anti-tumor are the two most widely reported activities of uracil analogues Pałasz A, Cież D. *Eur J Med Chem*. 2015;97:582—611.
16. Mancebo-Aracil J, Nájera C, Sansano JM. *Tetrahedron Asymmetry*. 2015;26:674—678.
17. Castelló LM, Nájera C, Sansano JM, Larrañaga O, de Cózar A, Cossío FP. *Adv Synth Catal*. 2014;356:3861—3870.
18. da Costa JCS, Pais KC, Fernandes EL, et al. *Arkivoc*. 2006;i:128—133.